Arbutus Biopharma Corporation (ABUS) Stock

Arbutus Biopharma Corporation (ABUS) is a Healthcare stock trading at $4.56 (as of 2026-06-18), with a market capitalization of $859.29M and a trailing P/E of 5.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Arbutus Biopharma Corporation is a biopharmaceutical company developing therapeutics for chronic hepatitis B virus infection and for SARS-CoV-2 and other coronaviruses. Its pipeline includes HBV candidates such as AB-729 and AB-836, along with additional oral programs including AB-161 and AB-101, with products and programs supported by collaborations and licensing agreements with multiple partners.

Valuation — source: SEC EDGAR (first-party)
Price$4.56
Market Cap$859.29M
P/E Ratio5.1
EV / EBITDA5.2
Price / Book3.23
Price / Sales4.40
DCF Value (model)$-3.36
DCF Upside vs Price-173.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$14.08M
Net Margin-237.9%
Return on Equity61.8%
Current Ratio54.26
Revenue Growth (YoY)128.2%
EPS Growth (YoY)-55.3%
FCF Growth (YoY)-39.1%
Financial Health — source: SEC EDGAR
Altman Z-Score9.16 (safe)
Valuation vs Sector & Industry
Stock P/E5.1
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-75.5%
vs Industry-70.3%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMORGAN STANLEY ($116.51M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOLindsay Androski
Employees19
CountryUS
IPO Date2014-03-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Compass Therapeutics, Inc. (CMPX)
  • Bicara Therapeutics Inc. Common Stock (BCAX)
  • OPKO Health, Inc. (OPK)
  • CorMedix Inc. (CRMD)
  • Enliven Therapeutics, Inc. (ELVN)
  • Kura Oncology, Inc. (KURA)
  • Nektar Therapeutics (NKTR)
ABUS earnings history · ABUS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.